Publicaciones en colaboración con investigadores/as de Heinrich Heine University Düsseldorf (15)

2024

  1. Non-apoptotic FAS signaling controls mTOR activation and extrafollicular maturation in human B cells

    Science Immunology, Vol. 9, Núm. 91

2021

  1. The Second Oncogenic Hit Determines the Cell Fate of ETV6-RUNX1 Positive Leukemia

    Frontiers in Cell and Developmental Biology, Vol. 9

  2. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

    Leukemia, Vol. 35, Núm. 3, pp. 835-849

2020

  1. Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study

    The Lancet Infectious Diseases, Vol. 20, Núm. 12, pp. 1409-1417

2019

  1. Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Lmo2 expression defines tumor cell identity during T-cell leukemogenesis

    EMBO Journal, Vol. 37, Núm. 14

  2. Loss of Pax5 exploits sca1-BCR-ABLp190 susceptibility to confer the metabolic shift essential for pB-ALL

    Cancer Research, Vol. 78, Núm. 10, pp. 2669-2679

2017

  1. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents

    Journal of Clinical Oncology, Vol. 35, Núm. 14, pp. 1591-1597

  2. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

    Oncotarget, Vol. 8, Núm. 43, pp. 73483-73500

2016

  1. Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia

    European Journal of Haematology, Vol. 97, Núm. 1, pp. 33-38

2015

  1. Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility

    Cancer Discovery, Vol. 5, Núm. 12, pp. 1328-1343

2013

  1. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: Position paper of an International Consortium and the European LeukemiaNet Working Group

    Leukemia and Lymphoma, Vol. 54, Núm. 3, pp. 472-475

2012

  1. Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group

    Leukemia, Vol. 26, Núm. 7, pp. 1730-1741

2009

  1. Standardization of flow cytometry in myelodysplastic syndromes: Report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

    Haematologica, Vol. 94, Núm. 8, pp. 1124-1134

2007

  1. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

    Leukemia Research